SACHS BRUCE I — SEC Form 4 filings
SEC reporting owner CIK 1197036. 18 Form 4 filings on record with FilingPulse; latest filed 2026-08-31.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-01-17 to 2026-08-31. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 5,000 shares, $1,948,416 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 12,368 shares, $5,858,564 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
- Largest priced transaction: sale of 7,073 shares @ $448.00 ($3,168,704) in VERTEX PHARMACEUTICALS INC / MA, filed 2024-05-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | Director | 18 | 2 legs · 5,000 sh · $1,948,416 | 2 legs · 12,368 sh · $5,858,564 | 19 |
Form 4 filings — SACHS BRUCE I
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-31 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Gift (G): 6,000 @ $0 | EDGAR |
| 2026-07-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 99.94 (derivative) @ $475.28 | EDGAR |
| 2026-05-05 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 2,866 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 107.34 (derivative) @ $442.50 | EDGAR |
| 2026-01-20 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 107.09 (derivative) @ $443.56 | EDGAR |
| 2025-10-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 115.77 (derivative) @ $410.31 | EDGAR |
| 2025-08-07 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Purchase (P): 1,634 @ $389.36 · Purchase (P): 3,366 @ $389.84 | EDGAR |
| 2025-07-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 101.21 (derivative) @ $469.34 | EDGAR |
| 2025-05-05 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 2,398 (derivative) @ $0 | EDGAR |
| 2025-04-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 95.47 (derivative) @ $497.51 | EDGAR |
| 2025-01-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 111.65 (derivative) @ $420.31 | EDGAR |
| 2024-10-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 90.32 (derivative) @ $484.39 | EDGAR |
| 2024-08-02 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Option exercise (M): 5,295 @ $125.71 · Sale (S): 5,295 @ $508 · Option exercise (M): 5,295 (derivative) @ $0 | EDGAR |
| 2024-07-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 89.26 (derivative) @ $490.12 | EDGAR |
| 2024-05-24 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Option exercise (M): 7,073 @ $93.51 · Sale (S): 7,073 @ $448 · Option exercise (M): 7,073 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 3,142 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 109.49 (derivative) @ $399.58 | EDGAR |
| 2024-01-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 101.04 (derivative) @ $432.99 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1197036 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →